Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Glioblastoma × ficlatuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Vascular Diseases 1 Pathologic Processes 1 Paraproteinemias 1 Neoplastic Processes 1 Neoplasms, Plasma Cell 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoproliferative Disorders 1 Lymphoma 1 Lymphatic Diseases 1 Liver Neoplasms 1 Liver Diseases 1 Leukemia, Myeloid, Acute 1 Immunoproliferative Disorders 1 Hemorrhagic Disorders 1 Hematologic Diseases 1 Gliosarcoma 1 Glioblastoma 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Cardiovascular Diseases 1 Carcinoma 1 Blood Protein Disorders 1

Interventions

Temozolomide 99 Radiotherapy 56 Radiation 26 Bevacizumab 17 Magnetic Resonance Spectroscopy 13 Nivolumab 11 Irinotecan 10 Cyclophosphamide 9 Surgical Procedures, Operative 8 Specimen Handling 8 pembrolizumab 7 motexafin gadolinium 7 Radiotherapy, Intensity-Modulated 7 Radiosurgery 7 O(6)-benzylguanine 7 Flucytosine 7 Chemotherapy, Adjuvant 7 sargramostim 6 poly ICLC 6 Leukapheresis 6 Erlotinib Hydrochloride 6 Carmustine 6 fludarabine 5 Radiotherapy, Conformal 5 Lomustine 5 Imiquimod 5 Imatinib Mesylate 5 Hydroxyurea 5 Drug Therapy 5 vocimagene amiretrorepvec 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01189513 2012-02-20

SCH-900105 in Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡